{"@id":"https://bioecon.ru/technology/universal-allogeneic-car-t/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://bioecon.ru/technology/universal-allogeneic-car-t/","json":"https://bioecon.ru/api/v1/technology/universal-allogeneic-car-t/index.json"},"id":"universal-allogeneic-car-t","industries":["advanced-therapies"],"lang":"ru","links":{"industries":["https://bioecon.ru/industries/advanced-therapies/"],"suppliers":["https://bioecon.ru/companies/johnson-johnson/","https://bioecon.ru/companies/ingenio-risaralda-sa/","https://bioecon.ru/companies/ipiranga-agroindustrial-sa/","https://bioecon.ru/companies/corporacion-montelimar/","https://bioecon.ru/companies/kolon-industries/","https://bioecon.ru/companies/pantaleon/","https://bioecon.ru/companies/alcoholes-del-istmo-internacional-sa/"]},"maturity":null,"name":"Универсальные аллогенные CAR-T","regions":["us","cn","eu"],"risk":"low","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-09-18","entity":"cellectis","kind":"vendor","urls":["https://allsci.com/news/expedited-pathways/cellectis-allogeneic-cd22-car-t-receives-fda-rmat-designation-for-relapsed-refractory-b-all/","https://finance.yahoo.com/sectors/healthcare/articles/cellectis-receives-fda-rmat-designation-203000364.html","https://ml.globenewswire.com/Resource/Download/774d0b7a-6940-4418-94f2-73049e7e4c74","https://www.cellectis.com/en/products/manufacturing","https://www.cellectis.com/uploads/files/Corporate_Presentation_-_March_2026.pdf","https://www.cellectis.com/uploads/files/Corporate_Presentation_-_May_2026_2.pdf","https://www.cellectis.com/uploads/files/Earnings_Q1_2026_PR_English.pdf","https://www.cellectis.com/uploads/files/PRESS_RELEASE-RMAT_designation.pdf"]},{"date":"2026-09-18","entity":"crispr-therapeutics","kind":"vendor","urls":["https://altindex.com/ticker/crsp/employees-linkedin","https://crisprtx.com/who-we-are","https://crisprtx.gcs-web.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-14","https://crisprtx.gcs-web.com/static-files/758a3569-9792-4af2-a773-f5e71afea36a","https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-provides-business-update-and-reports-first-7","https://ir.crisprtx.com/static-files/156e1fc1-277c-4ac7-a514-e90aa850a294","https://last10k.com/sec-filings/crsp/0001193125-26-330672.htm","https://pmc.ncbi.nlm.nih.gov/articles/PMC11305803/","https://profit.com/ticker/CRSP/profile","https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease","https://www.sec.gov/Archives/edgar/data/1674416/000119312526048957/R12.htm"]},{"date":"2026-09-18","entity":"artiva-biotherapeutics","kind":"vendor","urls":["https://investors.artivabio.com/News-and-Events/news/news-details/2026/Artiva-Biotherapeutics-Reports-First-Quarter-2026-Financial-Results-and-Recent-Business-Highlights/default.aspx","https://s203.q4cdn.com/960442723/files/doc_presentations/2026/Mar/10/Artiva-Corporate-Deck_March-2026.pdf","https://stockanalysis.com/stocks/artv/employees/","https://www.artivabio.com/nk-cell-technology/","https://www.artivabio.com/nk-cell-therapy-pipeline/","https://www.sec.gov/Archives/edgar/data/1817241/000119312524172230/d808948ds1.htm","https://www.stocktitan.net/sec-filings/ARTV/10-q-artiva-biotherapeutics-inc-quarterly-earnings-report-330c0f79d6d2.html"]}],"stages":[{"n":1,"title":"Донорский сорсинг"},{"n":2,"title":"Редактирование генов"},{"n":3,"title":"Инженерия и экспансия"},{"n":4,"title":"Банк и криохранение"},{"n":5,"title":"Выпускной контроль"},{"n":6,"title":"Клиническое развёртывание"}],"summary":"Готовые CAR- и NK-клетки, отредактированные от здоровых доноров - один выпуск, много пациентов. Таблица несёт трёх вендоров с леджер-досье; Allogene и Caribou названы в примечании до появления леджеров.","url":"/technology/universal-allogeneic-car-t/","verified":"2026-09-18"}